Healthcare
Solid Biosciences Inc.(SLDB)
Live Price
Offline$8.33
+13.95% today
1Y Change
+53.24%
Window
Jun 20, 2025 โ May 29, 2026
- Market Cap
- $560.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +35.0%
- Dividend Yield
- 0.0%
Coverage: 237 bars ยท Jun 20, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Solid Biosciences Inc. (SLDB) is a Healthcare stock with a market cap of $560.00M and listed on NASDAQ. The stock last traded around $8.33 and up 53.2% across the available one-year price window (Jun 20, 2025 โ May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +35.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +35.0%, free cash flow -56.4% with operating margin 0.0% and ROIC -89.1%. Stock Foundry combines SLDB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +35.0%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +1.8% | +12.9% | โ |
2026 Mar 19, 2026 | +2.0% | -1.3% | +8.6% | +21.2% |
2025 Nov 3, 2025 | -14.3% | -15.2% | -20.2% | -1.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLDB
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SLDB Max Drawdown
-44.41%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SLDB and SPY.
Company Overview
Solid Biosciences Inc.
NASDAQ Global Select
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Alexander G. Cumbo
- IPO Date
- Jan 26, 2018
- Employees
- 100
- Street Address
- 141 Portland Street
- Mailing
- Cambridge, MA, 02139
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 337 4680
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.8
Growth
- Revenue
- 0.0%
- EPS
- +35.0%
- Free Cash Flow
- -56.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -73.3%
- ROIC
- -89.1%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 6.14
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.